Adalimumab (Humira™): A promising monoclonal anti-tumor necrosis factor alpha in ophthalmology

被引：48
作者：
Neri P. [1 ,2 ,5 ]
Zucchi M. [3 ]
Allegri P. [4 ]
Lettieri M. [1 ,2 ]
Mariotti C. [1 ,2 ]
Giovannini A. [1 ,2 ]
机构：
[1] Eye Clinic, Azienda Ospedaliera, Universitaria-Ospedali Riuniti di Ancona, Ancona
[2] Ophthalmology Section, Neuroscience Department, Polytechnic University of Marche, Ancona
[3] Dermatology Clinic, Azienda Ospedaliera, Universitaria-Ospedali Riuniti di Ancona, Ancona
[4] Uveitis Center, Ophthalmology Department, Lavagna Hospital, Genoa
[5] Clinica Oculistica, Azienda Ospedaliera, Universitaria-Ospedali Riuniti di Ancona, 60100 Torrette-Ancona
来源：
International Ophthalmology | 2011年 / 31卷 / 2期
关键词：
Adalimumab; Immunosuppression; Macular oedema; Uveitis;
D O I：
10.1007/s10792-011-9430-3
中图分类号：
学科分类号：
摘要：
Tumor necrosis factor alpha (TNF-α) is a key soluble mediator involved in the inflammatory cascade of many disorders including uveitis. Among the anti-TNF-α agents, one of the most used in immune-mediated diseases, such as inflammatory arthropathies, is adalimumab (Humira ™, Abbott Pharmaceutical Inc.), a fully humanized antibody. The purpose of this review is to analyze the main pharmacological and clinical aspects of adalimumab and its efficacy both in systemic and ocular inflammatory disorders. Adalimumab was effective in treating several autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In recent years, adalimumab has been used successfully in refractory cases of intraocular inflammation. Moreover, this biological agent showed good safety and efficacy profiles in ocular use including childhood uveitis. Switching from other anti-TNF-α agents to adalimumab may offer several advantages, such as easier administration, better patient compliance, and lower rate of adverse events. Adalimumab is a promising drug for the therapy of uveitis, although further studies are needed on its application in uveitis. © Springer Science+Business Media B.V. 2011.
引用
收藏
页码：165 / 173
页数：8
相关论文
共 52 条
[1]  
Vassalli P., The pathophysiology of tumor necrosis factors, Annu Rev Immunol, 10, pp. 411-452, (1992)
[2]  
Chen G., Goeddel D.V., TNF-R1 signaling: A beautiful pathway, Science, 296, 5573, pp. 1634-1635, (2002)
[3]  
Saklatvala J., Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage, Nature, 322, pp. 547-549, (1986)
[4]  
Selmaj K.W., Raine C.S., Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro, Annals of Neurology, 23, 4, pp. 339-346, (1988)
[5]  
Nussenblatt R.B., Proctor Lecture. Experimental autoimmune uveitis: Mechanisms of disease and clinical therapeutic indications, Invest Ophthalmol Vis Sci, 32, pp. 3131-3141, (1991)
[6]  
Forrester J.V., Duke-Elder lecture: New concepts on the role of autoimmunity in the pathogenesis of uveitis, Eye, 6, pp. 433-446, (1992)
[7]  
Caspi R.R., Roberge F.G., McCallister C.G., T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat, Journal of Immunology, 136, 3, pp. 928-933, (1986)
[8]  
Nakamura S., Yamakawa T., Sugita M., Kijima M., Ishioka M., Tanaka S.-I., Ohno S., The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice, Investigative Ophthalmology and Visual Science, 35, 11, pp. 3884-3889, (1994)
[9]  
Sartani G., Silver P.B., Rizzo L.V., Chan C.-C., Wiggert B., Mastorakos G., Caspi R.R., Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming, Investigative Ophthalmology and Visual Science, 37, 11, pp. 2211-2218, (1996)
[10]  
Santos L.M., Marcos M.C., Gallardo G.J.M., Gomez V.M.A., Collantes E.E., Ramirez C.R., Omar M.M., Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis, Ophthalmic Research, 33, 5, pp. 251-255, (2001)
123456